Content
December 2018, Volume 2, Issue 4
- 357-358 Including Future Consumption and Production in Economic Evaluation of Interventions that Save Life-Years: Commentary
by Erik Nord & Christoffer Lamøy - 359-369 Longitudinal Effects of Adjuvant Endocrine Therapy on the Quality of Life of Post-menopausal Women with Non-metastatic ER+ Breast Cancer: A Systematic Review
by Hong Xiao & Xinyi Jiang & Cheng Chen & Alberto J. Montero & Vakaramoko Diaby - 371-380 Cost-Effectiveness of Aspirin Adherence for Secondary Prevention of Cardiovascular Events
by Laurence M. Djatche & Stefan Varga & Robert D. Lieberthal - 381-392 Functional Status and Well-Being in People with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Compared with People with Multiple Sclerosis and Healthy Controls
by Caroline C. Kingdon & Erinna W. Bowman & Hayley Curran & Luis Nacul & Eliana M. Lacerda - 393-402 Healthcare Cost Development in a Type 2 Diabetes Patient Population on Glucose-Lowering Drug Treatment: A Nationwide Observational Study 2006–2014
by David Nathanson & Ugne Sabale & Jan W. Eriksson & Thomas Nyström & Anna Norhammar & Urban Olsson & Johan Bodegård - 403-413 Which Costs Matter? Costs Included in Economic Evaluation and their Impact on Decision Uncertainty for Stable Coronary Artery Disease
by James Lomas & Miqdad Asaria & Laura Bojke & Chris P. Gale & Gerry Richardson & Simon Walker - 415-421 Out-of-Pocket Household Expenditures on Medical Injections in Cambodia
by Sachiko Ozawa & Tatenda T. Yemeke & Alie F. Tawah & Vivek Kulkarni & Manuela Villar Uribe - 423-432 Utilization and Expenditure of Anti-cancer Medicines in Kosovo: Findings and Implications
by Arianit Jakupi & Brian Godman & Antony Martin & Alan Haycox & Indrit Baholli - 433-442 The Healthcare Cost Burden of Acute Myocardial Infarction in Alberta, Canada
by Dat T. Tran & Arto Ohinmaa & Nguyen X. Thanh & Robert C. Welsh & Padma Kaul - 443-458 An Exploratory Study: A Head-to-Head Comparison of the EQ-5D-5L and AQoL-8D for Long-Term Publicly Waitlisted Bariatric Surgery Patients Before and 3 Months After Bariatric Surgery
by Julie A. Campbell & Martin Hensher & Amanda Neil & Alison Venn & Petr Otahal & Stephen Wilkinson & Andrew J. Palmer - 459-467 The Cost of Patients with Chronic Kidney Failure Before Dialysis: Results from the IRIDE Observational Study
by Claudio Jommi & Patrizio Armeni & Margherita Battista & Paolo Procolo & Giuseppe Conte & Claudio Ronco & Mario Cozzolino & Anna Maria Costanzo & Umberto Luzio Paparatti & Gabriella Concas & Giuseppe Remuzzi
September 2018, Volume 2, Issue 3
- 221-224 Hospital Pharmacists in Europe: Between Warehouse and Prescription Pad?
by Livio Garattini & Anna Padula - 225-231 Developing Accessible, Pictorial Versions of Health-Related Quality-of-Life Instruments Suitable for Economic Evaluation: A Report of Preliminary Studies Conducted in Canada and the United Kingdom
by David G. T. Whitehurst & Nicholas R. Latimer & Aura Kagan & Rebecca Palmer & Nina Simmons-Mackie & J. Charles Victor & Jeffrey S. Hoch - 233-239 A Review of Clinical and Economic Evaluations Applied to Psychotropic Therapies Used in the Treatment of Schizophrenia in Argentina
by Gisela Paula González & Nebel Silvana Moscoso & Fernando Pablo Lago - 241-253 The Cost Effectiveness of Lubiprostone in Chronic Idiopathic Constipation
by Becky Pennington & Emily-Ruth Marriott & Peter Lichtlen & Ayesha Akbar & Anthony J. Hatswell - 255-270 The Potential Clinical and Economic Value of Primary Tumour Identification in Metastatic Cancer of Unknown Primary Tumour: A Population-Based Retrospective Matched Cohort Study
by Malek B. Hannouf & Eric Winquist & Salaheddin M. Mahmud & Muriel Brackstone & Sisira Sarma & George Rodrigues & Peter K. Rogan & Jeffrey S. Hoch & Gregory S. Zaric - 271-280 Cost Effectiveness of Stapled Haemorrhoidopexy and Traditional Excisional Surgery for the Treatment of Haemorrhoidal Disease
by Mary M. Kilonzo & Steven R. Brown & Hanne Bruhn & Jonathan A. Cook & Jemma Hudson & John Norrie & Angus J. M. Watson & Jessica Wood - 281-296 Out-of-Pocket Expenditures, Indirect Costs and Health-Related Quality of Life of Patients with Pulmonary Tuberculosis in Thailand
by Pimwara Tanvejsilp & Mark Loeb & Jonathan Dushoff & Feng Xie - 297-308 Healthcare Resource Uses and Out-of-Pocket Expenses Associated with Pulmonary TB Treatment in Thailand
by Pimwara Tanvejsilp & Mark Loeb & Jonathan Dushoff & Feng Xie - 309-323 Using Cerebrospinal Fluid Biomarker Testing to Target Treatment to Patients with Mild Cognitive Impairment: A Cost-Effectiveness Analysis
by Tzeyu L. Michaud & Robert L. Kane & J. Riley McCarten & Joseph E. Gaugler & John A. Nyman & Karen M. Kuntz - 325-335 Impact of Fluid Choice in Systemic Inflammatory Response Syndrome Patients on Hospital Cost Savings
by Suzanne Laplante & Dilip U. Makhija & Sibyl H. Munson & Victor S. Khangulov & Fred W. Peyerl & Scott M. Paluszkiewicz & Aditi J. Ravindranath & Carol R. Schermer - 337-345 Evaluation of Health Status of Type 2 Diabetes Outpatients Receiving Care in a Tertiary Hospital in Nigeria
by Maxwell Ogochukwu Adibe & Chibueze Anosike & Sunday Odunke Nduka & Abdulmuminu Isah - 347-354 Cost Analysis of a Digital Health Care Model in Sweden
by Björn Ekman
June 2018, Volume 2, Issue 2
- 87-91 The Impact of Brexit on Pharmaceuticals and HTA
by Paula K Lorgelly - 93-95 Raise the Bar, Not the Threshold Value: Meeting Patient Preferences for Palliative and End-of-Life Care
by Nikki McCaffrey & Simon Eckermann - 97-107 Does Methodological Guidance Produce Consistency? A Review of Methodological Consistency in Breast Cancer Utility Value Measurement in NICE Single Technology Appraisals
by Micah Rose & Stephen Rice & Dawn Craig - 109-123 Risk-Sharing Agreements in the EU: A Systematic Review of Major Trends
by Trevor Jozef Piatkiewicz & Janine Marie Traulsen & Tove Holm-Larsen - 125-139 The Economic Burden of Small Cell Lung Cancer: A Systematic Review of the Literature
by Ashley Enstone & Maire Greaney & Manca Povsic & Robin Wyn & John R. Penrod & Yong Yuan - 141-151 Economic Evaluation of Midazolam–Droperidol Combination, Versus Droperidol or Olanzapine for the Management of Acute Agitation in the Emergency Department: A Within-Trial Analysis
by Celene Y. L. Yap & Ya-seng (Arthur) Hsueh & Jonathan C. Knott & David McD Taylor & Esther W. Chan & David C. M. Kong - 153-163 Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
by Martina Garau & Grace Hampson & Nancy Devlin & Nicola Amedeo Mazzanti & Antonio Profico - 165-177 Direct Mapping of the QLQ-C30 to EQ-5D Preferences: A Comparison of Regression Methods
by Ralph Crott - 179-190 Cost of Intensive Care Treatment for Liver Disorders at Tertiary Care Level in India
by Shankar Prinja & Pankaj Bahuguna & Ajay Duseja & Manmeet Kaur & Yogesh Kumar Chawla - 191-201 Resources and Costs Associated with the Treatment of Advanced and Metastatic Gastric Cancer in the Mexican Public Sector: A Patient Chart Review
by Miguel Quintana & José A. Toriz & Diego Novick & Kyla Jones & Brenda S. Botello & Juan Alejandro Silva - 203-208 Health-Related Quality of Life in Patients Treated with Continuous Ambulatory Peritoneal Dialysis and Automated Peritoneal Dialysis in Singapore
by F. Yang & N. Luo & T. Lau & Z. L. Yu & M. W. Y. Foo & K. Griva - 209-219 Direct Medical Costs of Type 2 Diabetes in France: An Insurance Claims Database Analysis
by Bernard Charbonnel & Dominique Simon & Jean Dallongeville & Isabelle Bureau & Sylvie Dejager & Laurie Levy-Bachelot & Julie Gourmelen & Bruno Detournay
March 2018, Volume 2, Issue 1
- 1-3 Health Technology Assessment for Policy Making in India: Current Scenario and Way Forward
by Shankar Prinja & Laura E. Downey & Vijay K. Gauba & Soumya Swaminathan - 5-17 Application of Discrete-Choice Experiment Methods in Tobacco Control: A Systematic Review
by Kabindra Regmi & Dinesh Kaphle & Sabina Timilsina & Nik Annie Afiqah Tuha - 19-29 Economic Evaluation of Bevacizumab for Treatment of Platinum-Resistant Recurrent Ovarian Cancer in Canada
by Graeme Ball & Feng Xie & Jean-Eric Tarride - 31-41 Comparison of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of Healthcare Resource Utilization and Relapse Rates from US Insurance Claims Data
by Jacqueline Nicholas & Aaron Boster & Ning Wu & Wei-Shi Yeh & Monica Fay & Jon Kendter & Ming-Yi Huang & Andrew Lee - 43-51 Weighting Health Outcomes by Socioeconomic Position Using Stated Preferences
by Anita Lal & Mohammad Siahpush & Marjory Moodie & Anna Peeters & Robert Carter - 53-61 Assessing Variation in the Cost of Palivizumab for Respiratory Syncytial Virus Prevention in Preterm Infants
by Ahva Shahabi & Desi Peneva & Devin Incerti & Kimmie McLaurin & Warren Stevens - 63-76 An Exploratory Study of Long-Term Publicly Waitlisted Bariatric Surgery Patients’ Quality of Life Before and 1 Year After Bariatric Surgery, and Considerations for Healthcare Planners
by Julie A. Campbell & Martin Hensher & Amanda Neil & Alison Venn & Stephen Wilkinson & Andrew J. Palmer - 77-85 Reliability and Validity of the Greek Migraine Disability Assessment (MIDAS) Questionnaire
by Theodora Oikonomidi & Michail Vikelis & Artemios Artemiadis & George P. Chrousos & Christina Darviri
December 2017, Volume 1, Issue 4
- 233-239 Statistical Alchemy: Conceptual Validity and Mapping to Generate Health State Utility Values
by Jeff Round & Annie Hawton - 241-253 Choosing Between Unicompartmental and Total Knee Replacement: What Can Economic Evaluations Tell Us? A Systematic Review
by Edward Burn & Alexander D. Liddle & Thomas W. Hamilton & Sunil Pai & Hemant G. Pandit & David W. Murray & Rafael Pinedo-Villanueva - 255-263 Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR)
by Lisa Masucci & Jaclyn Beca & Mona Sabharwal & Jeffrey S. Hoch - 265-278 Utilization of Intergovernmental Funds to Implement Maternal and Child Health Plans of a Multi-Strategy Community Intervention in Haryana, North India: A Retrospective Assessment
by Madhu Gupta & Federica Angeli & Hans Bosma & Shankar Prinja & Manmeet Kaur & Onno C. P. Schayck - 279-290 Economic Evaluation of Fulvestrant 500 mg Compared to Generic Aromatase Inhibitors in Patients with Advanced Breast Cancer in Sweden
by Ugne Sabale & Mattias Ekman & Daniel Thunström & Claire Telford & Christopher Livings - 291-300 Eliciting the Monetary Value of a Quality-Adjusted Life Year in a Greek Outpatient Department in Times of Economic Austerity
by A. Mavrodi & V. Aletras & A. Spanou & D. Niakas - 301-314 Development of a Procedure for the Government Provision of Bone-Anchored Prosthesis Using Osseointegration in Australia
by Laurent Frossard & Gregory Merlo & Tanya Quincey & Brendan Burkett & Debra Berg
September 2017, Volume 1, Issue 3
- 145-147 Can Price Transparency Contribute to More Affordable Patient Access to Medicines?
by Sabine Vogler & Kenneth R. Paterson - 149-165 Model-Based Economic Evaluation of Treatments for Depression: A Systematic Literature Review
by Spyros Kolovos & Judith E. Bosmans & Heleen Riper & Karine Chevreul & Veerle M. H. Coupé & Maurits W. Tulder - 167-173 Differences in Incremental Cost-Effectiveness Ratios for Common Versus Rare Conditions: A Case from Oncology
by Kavisha Jayasundara & Murray Krahn & Muhammad Mamdani & Jeffrey S. Hoch & Paul Grootendorst - 175-184 Cost-Effectiveness of Haemorrhoidal Artery Ligation versus Rubber Band Ligation for the Treatment of Grade II–III Haemorrhoids: Analysis Using Evidence from the HubBLe Trial
by Abualbishr Alshreef & Allan J. Wailoo & Steven R. Brown & James P. Tiernan & Angus J. M. Watson & Katie Biggs & Mike Bradburn & Daniel Hind - 185-194 Evaluating the Treatment Costs for Uncomplicated Malaria at a Public Healthcare Facility in Nigeria and the Implications
by Charles C. Ezenduka & Daniel Resende Falleiros & Brian B. Godman - 195-202 Cost of Illness of Japanese Patients with Chronic Lymphocytic Leukemia (CLL), and Budget Impact of the Market Introduction of Ibrutinib
by Jörg Mahlich & Shinichiro Okamoto & Akiko Tsubota - 203-221 Health System Efficiency: A Fragmented Picture Based on OECD Data
by Andreas Behr & Katja Theune - 223-229 Cost-Minimisation Analysis of Erythropoiesis-Stimulating Agents in the Treatment of Anaemia in Dialysed Patients: A Pilot Study
by Astrid Darsonval & Virginie Besson & Claire Cavalin
June 2017, Volume 1, Issue 2
- 73-77 Model Registration: A Call to Action
by Christopher James Sampson & Tim Wrightson - 79-97 Handling Missing Data in Within-Trial Cost-Effectiveness Analysis: A Review with Future Recommendations
by Andrea Gabrio & Alexina J. Mason & Gianluca Baio - 99-108 Issues Related to the Frequency of Exploratory Analyses by Evidence Review Groups in the NICE Single Technology Appraisal Process
by Eva Kaltenthaler & Christopher Carroll & Daniel Hill-McManus & Alison Scope & Michael Holmes & Stephen Rice & Micah Rose & Paul Tappenden & Nerys Woolacott - 109-115 A Comparison of Inpatient Cost Per Day in General Surgery Patients with Type 2 Diabetes Treated with Basal-Bolus versus Sliding Scale Insulin Regimens
by Victoria L. Phillips & Anwar L. Byrd & Saira Adeel & Limin Peng & Dawn D. Smiley & Guillermo E. Umpierrez - 117-121 Cost-Benefit Analysis of Telemedicine Systems/Units in Greek Remote Areas
by Marios-Nikolaos Kouskoukis & Charalambos Botsaris - 123-131 Utilization, Spending, and Price Trends for Quinolones in the US Medicaid Programs: 25 Years’ Experience 1991–2015
by Ziyad S. Almalki & Xiaomeng Yue & Ying Xia & Patricia R. Wigle & Jeff Jianfei Guo - 133-141 Early Assessment of the Likely Cost Effectiveness of Single-Use Flexible Video Bronchoscopes
by Christoffer Lilja Terjesen & Julia Kovaleva & Lars Ehlers - 143-143 Erratum to: Handling Missing Data in Within-Trial Cost-Effectiveness Analysis: A Review with Future Recommendations
by Andrea Gabrio & Alexina J. Mason & Gianluca Baio
March 2017, Volume 1, Issue 1
- 1-12 The Potential Cost-Effectiveness of HIV Vaccines: A Systematic Review
by Blythe Adamson & Dobromir Dimitrov & Beth Devine & Ruanne Barnabas - 13-23 Communal Sharing and the Provision of Low-Volume High-Cost Health Services: Results of a Survey
by Jeff Richardson & Angelo Iezzi & Gang Chen & Aimee Maxwell - 25-36 Economic Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder in the UK
by Jameel Nazir & Malin Berling & Charles McCrea & Francis Fatoye & Sally Bowditch & Zalmai Hakimi & Adrian Wagg - 37-51 Population Screening for Hereditary Haemochromatosis in Australia: Construction and Validation of a State-Transition Cost-Effectiveness Model
by Barbara Graaff & Lei Si & Amanda L. Neil & Kwang Chien Yee & Kristy Sanderson & Lyle C. Gurrin & Andrew J. Palmer - 53-63 A Single-Center Cost Analysis of Treating Primary and Metastatic Brain Cancers with Either Brain Laser Interstitial Thermal Therapy (LITT) or Craniotomy
by Eric C. Leuthardt & Jeff Voigt & Albert H. Kim & Pete Sylvester - 65-68 Forecasting Pharmaceutical Prices for Economic Evaluations When There Is No Market: A Review
by Ilke Akpinar & Philip Jacobs & Tien Dat Tran - 69-70 Comment on: “Forecasting Pharmaceutical Prices for Economic Evaluations When There is No Market: A Review”
by Przemysław Holko - 71-71 Authors’ Reply to Holko: “Forecasting Pharmaceutical Prices for Economic Evaluations When There Is No Market: A Review”
by Ilke Akpinar & Philip Jacobs & Dat T. Tran